Stage 4 restrictions (11:59 pm Fri 12th Feb - 11:59pm Wed 17th Feb)
Dear MCEM Users,
As many of you will be aware, Stage 4 restrictions have been announced for Victoria, starting from 11:59 pm tonight (Friday 12th February), ending on 11:59pm Wednesday 17th February.
Critical information for MCEM Users for the period of this lockdown is as follows:
· Access to MCEM is limited to existing users undertaking Essential Research as defined in the University Covid-19 Updates Fact Sheet 12/2/21 and copied below.
· All training will be rescheduled to occur after the lockdown.
· MCEM staff will be working from home, except where necessary to support essential activities. As always, staff are available during business hours via email and phone.
· All existing bookings in iLab will be cancelled (otherwise iLab automatically charges you). If your research meets the Essential Research criteria, please contact the relevant instrument manager to make a business hours booking if necessary during the lockdown period.
We will provide a further update as we hear more from the State Government and from Monash University. As always, please contact us if you have any queries via email@example.com.
We very much hope we will be welcoming everyone back next Thursday.
Definition of Essential Research - University Covid-19 Updates Fact Sheet 12/2/21
“Essential Research” is defined by one of the following four principles:
· Principle 1: the storage and management of existing samples and data research, infrastructure that are temperature and environmentally sensitive;
· Principle 2: management and care of critical living resources, and the equipment and materials they depend upon;
· Principle 3: research addressing the impact of COVID-19 and research in support of the hospital and broader health system;
· Principle 4: long-term experiments or studies that otherwise would be prohibitive to restart.
o Examples of research that aligns with these principles are: research to support clinical trials in serious diseases such as cancer, leukemia and lymphoma; drug discovery and development activities such as the development of inhaled oxytocin; university platforms to facilitate these activities such as MARP, the Centre for Drug Candidate Optimisation (CDCO) and the Monash Genome Modification Platform; collaborative research programs that support partners (and jobs) in health-related industries.
o Additionally, any COVID-19 related research and provision of parts or supplies for equipment needed to treat patients with COVID-19; or help them to recover – like the printing of parts for ventilator machines.